Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.

Fiche publication

Date publication

août 2026

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr FUMET Jean-David

Tous les auteurs :
Heurtier V, Macouillard P, Ray-Coquard I, Sabatier R, Lebreton C, Augereau P, Penault-Llorca F, Joly F, Follana P, Pautier P, Frenel JS, Gladieff L, De La Motte Rouge T, Savoye AM, Petit T, Quesada S, Fumet JD, Guillemet C, Leguay C, Becourt S, Bosquet L, Rodrigues M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42660771

Résumé

We aimed to describe real-world outcomes of chemotherapy with or without bevacizumab in patients with platinum-resistant high-grade serous ovarian, peritoneal, or fallopian tube carcinoma and to identify prognostic factors.